Inaphaea BioLabs

September is Gynaecological Cancer Awareness Month, which is dedicated to educating, raising awareness and supporting women facing gynaecological cancer. At Inaphaea, we are dedicated to comprehensively understanding our drug candidates during the discovery and preclinical phases of development. Our goal is to support decision-making in translational drug development for therapeutic areas within oncology. Hypoxia (low oxygen within the tumour) is a key driver of ovarian cancer progression and development of metastatic disease (National Library of Medicine (NLM)). At Inaphaea our drug testing services are available under both Normoxia (normal oxygen) and Hypoxia across our range of 470 Patient Derived Cell lines which includes over 80 specific ovarian cancers. We also have several endometrial and fallopian cancer PDCs. Read more about how we're supporting translational drug development for gynaecological oncology in our latest blog: https://bit.ly/3z7ATGf #GynaecologicalCancerAwarenessMonth #CancerResearch #DrugDevelopment #CancerAwareness

Evaluation and commercial use agreement announcement. We are pleased to confirm the execution of a second evaluation and commercial use agreement with UK-based DLOC Biosystems. This agreement involves supplying Inaphaea's patient-derived cells (PDCs) for evaluation and commercial use within DLOC's state-of-the-art organ-on-a-chip technology. Initially, the contract focuses on the development of up to four glioblastoma and one triple-negative breast cancer in-vitro 3D tumour models. These models will then be offered for commercial services by both DLOC and Inaphaea. Additional PDCs from Inaphaea's portfolio of 66 cancer types can be incorporated at any time. Mark Eccleston, Director of Inaphaea BioLabs comments: "This second deal to exploit Inaphaea's Patient Derived Cell bank demonstrates the interest in our biobank and we look forward to developing the next generation of in-vitro drug evaluation systems with DLOC." Read more about the agreement here: https://lnkd.in/erKar2vi #PDCs #BioTech #DrugDiscovery #Assays #AssayDevelopment

In case you missed it, we recently announced the execution of an evaluation and commercial use agreement with Swedish contract research organisation BioReperia. Mark Eccleston, Director of Inaphaea BioLabs comments: "This deal represents a great step forward in commercialising Inaphaea's primary asset - its Patient Derived Cell bank. Productising Inaphaea's cell bank is a key strategic objective." This agreement represents an important initial move toward broadening the market for Inaphaea’s PDC bank as a product, in addition to its current service offerings. Read more about the agreement here: https://lnkd.in/e-XzpQrb #PDCs #BioTech #DrugDiscovery #Assays #AssayDevelopment

Harnessing the potential of patient-derived cells (PDCs) for immuno-oncology research. Inaphaea offers pharmaceutical partners specialised cell-based assays designed for early-stage drug discovery and pre-clinical research. Our PDCs are integral for advancing personalised treatments in immuno-oncology, supporting the development of tumour models, organoids, and immune cell-based therapies. Explore how our PDC models compare to traditional oncology models on our website: https://bit.ly/3tHHLXD #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #PDCs

Evaluation and commercial use agreement announcement. We are pleased to confirm the execution of an evaluation and commercial use agreement with Swedish contract research organisation BioReperia. This is the first commercial agreement for the use of Inaphaea’s Patient Derived Cells (PDCs) which centres on their use in BioReperia’s advanced in-vivo ZTX® platform for drug development. This collaboration will offer expanded services for glioblastoma models, with the potential to include more cancer types from Inaphaea’s extensive bank of 470 PDCs. This is an important first step in expanding the market for Inaphaea’s PDC bank as a product, in parallel with the service element of the business. Read more about the agreement here: https://lnkd.in/e-XzpQrb #PDCs #BioTech #DrugDiscovery #Assays #AssayDevelopment

Pre-formulation and formulation development expertise. Working in tandem with our collaboration partner Agility Life Sciences, formulation development and pre-formulation checks can be seamlessly integrated into Inaphaea’s cell-based services, ensuring that your molecules are ready for Inaphaea’s cell-based assays; or using Inaphaea’s services to confirm your new formulation remains bioactive. Learn more about our pre-formulation and formulation development capabilities here: https://bit.ly/3yO2dZP #BioTech #DrugDiscovery #Assays #AssayDevelopment

Meet Inaphaea at the Oncology Venture, Innovation and Partnering Summit. As part of our plans to expand our reach and connect with potential customers around the world, the Inaphaea team is pleased to be attending the summit from 9-10 October in Cambridge, Massachusetts. The summit provides delegates with the opportunity to connect with future investors and partners and gain strategic insights on funding activities and innovation strategies in cancer therapeutics and diagnostics. We are particularly looking forward to speaking to US businesses about Inaphaea's capabilities, which include our available 2D and 3D PDC models, alongside our immuno-oncology assays. Attending the summit is Inaphaea BioLabs' Director and CEO of parent company ValiRx, Dr Mark Eccleston. Mark is a polymer chemist and biotechnology entrepreneur with over 30 years of experience in drug and biomarker development. If you'd like to book a meeting with Mark, contact us here: https://lnkd.in/gjWnzYYe Cambridge VIP: Venture, Innovation & Partnering #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #Event #Networking #OncologyVIP

At Inaphaea BioLabs, we work with our partner Physiomics plc to provide biological modelling and advanced statistical analysis. Data generated by Inaphaea can be seamlessly integrated into the Physiomics modelling capability for biological modelling and advanced data interpretation. To learn more about how our combined capabilities can enhance your projects, speak to a member of the Inaphaea team: https://bit.ly/3sn67W4 #BioTech #DrugDiscovery #Assays #AssayDevelopment

Harnessing the power of immunoassays for immuno-oncology. Immuno assays play a crucial role in advancing cancer research by enabling the precise measurement of immune responses to tumours. At Inaphaea BioLabs, we utilise a range of specialised assays to assess cellular activity, alongside hormones or cytokines released by cells on stimulation. As an extension of your research team, we aim to make interaction easy from the project's outset through to completion. Find out more about our immunoassay capabilities on our website: https://bit.ly/3YDIshY #ImmunoOncology #BioTech #DrugDiscovery #Assays

Custom immunoassay service development. In addition to our pre-validated models, our custom immunoassay services are designed to address specialised needs in immuno-oncology. We offer complete development, qualification, and validation of custom assays tailored to your research requirements in cancer immunotherapy. An important element of our overall service delivery is our direct-to-scientist communication access. As an extension of your research team, we aim to make interaction easy from the project's outset through to completion. Find out more: https://bit.ly/3YDIshY #ImmunoOncology #BioTech #DrugDiscovery #Assays